Evolution of randomized trials in advanced/metastatic soft tissue sarcoma: End point selection, surrogacy, and quality of reporting

Alona Zer*, Rebecca M. Prince, Eitan Amir, Albiruni Abdul Razak

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Purpose Randomized controlled trials (RCTs) in soft tissue sarcoma (STS) have used varying end points. The surrogacy of intermediate end points, such as progression-free survival (PFS), response rate (RR), and 3-month and 6-month PFS (3moPFS and 6moPFS) with overall survival (OS), remains unknown. The quality of efficacy and toxicity reporting in these studies is also uncertain. Methods A systematic review of systemic therapy RCTs in STS was performed. Surrogacy between intermediate end points and OS was explored using weighted linear regression for the hazard ratio for OS with the hazard ratio for PFS or the odds ratio for RR, 3moPFS, and 6moPFS. The quality of reporting for efficacy and toxicity was also evaluated. Results Fifty-two RCTs published between 1974 and 2014, comprising 9,762 patients, met the inclusion criteria. There were significant correlations between PFS and OS (R = 0.61) and between RR and OS (R = 0.51). Conversely, there were nonsignificant correlations between 3moPFS and 6moPFS with OS. A reduction in the use of RR as the primary end point was observed over time, favoring time-based events (P for trend =.02). In 14% of RCTs, the primary end point was not met, but the study was reported as being positive. Toxicity was comprehensively reported in 47% of RCTs, whereas 14% inadequately reported toxicity. Conclusion In advanced STS, PFS and RR seem to be appropriate surrogates for OS. There is poor correlation between OS and both 3moPFS and 6moPFS. As such, caution is urged with the use of these as primary end points in randomized STS trials. The quality of toxicity reporting and interpretation of results is suboptimal.

Original languageEnglish
Pages (from-to)1469-1475
Number of pages7
JournalJournal of Clinical Oncology
Volume34
Issue number13
DOIs
StatePublished - 1 May 2016
Externally publishedYes

Fingerprint

Dive into the research topics of 'Evolution of randomized trials in advanced/metastatic soft tissue sarcoma: End point selection, surrogacy, and quality of reporting'. Together they form a unique fingerprint.

Cite this